Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.
Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.
Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.
Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.
Gujarat Themis Biosyn Limited (GUJTHEM) reports Q2 FY27 revenue up 12% YoY, new fermentation facility commissioned.
Biocon Limited's Q2 FY27 results show a 2% revenue increase, with EBITDA margin decline; strong biosimilars and generics performance.
Biocon Limited (BIOCON) reports Q2FY27 total income at Rs 4,423 Cr, up 1% YoY. Biopharma revenue up 5%.
Anthem Biosciences Limited (NSE: ANTHEM) reports strong Q2 & H1 FY27 results with consolidated revenue up 7.2% and EBITDA margins at 50.6%.
Lyka Labs Limited (LYKALABS) reports a 34% revenue surge and a 136% net profit increase in Q2FY27.
OneSource Specialty Pharma Limited (NSE: ONESOURCE) receives USFDA EIR with VAI classification for its Bengaluru facility, marking successful completion of i.